m6A-centered Drug Response Information
General Information of the Drug (ID: M6APDG01914)
Name |
Nevirapine
|
||||
---|---|---|---|---|---|
Synonyms |
11-CYCLOPROPYL-5,11-DIHYDRO-4-METHYL-6H-DIPYRIDO[3,2-B:2',3'-E][1,4]DIAZEPIN-6-ONE; 11-Cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[2,3-e:3',2'-b][1,4]diazepin-6-one; 11-Cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[2,3-e:3',2'-b][1,4]diazepin-6-one & PRO 140 (Anti-CCR5 monoclonal antibody); 11-Cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one; 11-Cyclopropyl-5,11-dihydro-4-methyl-6H-dipyrido(3,2-b:2',3'-e)(1,4)diazepin-6-one; BI RG 587; BI-RG-587; BI-RG-587 & CD4-IgG; BIRG 0587; BIRG 587; BIRG-0587; BIRG-587; BIRG587; Cahill May Roberts Brand of Nevirapine; N11-Cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e]-[1,4]diazepin-6-one & CD4-immunoadhesin; NEV; NON-NUCLEOSIDE RT INHIBITOR NEVIRAPINE; NVP; Nevirapine & CD4-IgG; Nevirapine & PRO 140; Nevirapine (JAN/USP/INN); Nevirapine [USAN:INN]; Promeco Brand of Nevirapine; Viramune; Viramune (TN); Viramune(TM); Viramune, BI-RG 587, Nevirapine
Click to Show/Hide
|
||||
Status |
Approved
|
||||
Structure |
|
||||
Formula |
C15H14N4O
|
||||
InChI |
1S/C15H14N4O/c1-9-6-8-17-14-12(9)18-15(20)11-3-2-7-16-13(11)19(14)10-4-5-10/h2-3,6-8,10H,4-5H2,1H3,(H,18,20)
|
||||
InChIKey |
NQDJXKOVJZTUJA-UHFFFAOYSA-N
|
||||
PubChem CID | |||||
VARIDT Drug ID |
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
P-glycoprotein 1 (ABCB1)
Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3)
In total 1 mechanisms lead to this potential drug response | ||||
Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Nevirapine. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Nevirapine through regulating the expression of P-glycoprotein 1 (ABCB1). | [1], [2] | ||
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response | ||||
Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Nevirapine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Nevirapine through regulating the expression of P-glycoprotein 1 (ABCB1). | [2], [3] | ||
References